JBDI Holdings Limited Announces US$1.0 Million Share Repurchase Program
The Company's proposed repurchases may be made from time to time on the open market at prevailing market prices, in privately negotiated transactions, in block trades and/or through other legally permissible means, depending on market conditions and in accordance with applicable rules and regulations. The Board will review the share repurchase program periodically, and may authorize adjustment of its terms and size.
About JBDI Holdings Limited
JBDI Holdings Limited is a leading provider of environmentally friendly and efficient products and services, specializing in the revitalization, reconditioning, and recycling of drums and related containers in Singapore and across Southeast Asia. With nearly four decades of industry experience, JBDI Holdings has established a strong reputation for quality and reliability, offering a wide range of reconditioned steel and plastic drums, new containers, and ancillary services. Our mission is to help our customers achieve a zero environmental impact footprint while optimizing resource allocation and reducing costs. For more information, please visit https://www.barrels.com.sg.
Safe Harbor Statement
This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private SecuritiesLitigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'confident' and similar statements. JBDI may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the 'SEC'), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about CBDI's beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. JBDI undertakes no obligation to update any forward-looking statement, except as required under applicable law.
Investor Relations Contact:Matthew Abenante, IRCPresidentStrategic Investor Relations, LLC Tel: 347-947-2093Email: matthew@strategic-ir.com
Liang Zhao RongJBDI Holdings LimitedTel: +65 6861 4150Email: zhaorong.liang@eugroup.com.sgSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
Here's what Warren Buffett says will be the ultimate growth industry!
Artificial intelligence (AI) has a lot of investors excited right now, yet billionaire investor Warren Buffett isn't one of them. Despite owning shares in companies such as Apple (NASDAQ:AAPL) and Amazon, none of these investments were made solely based on their AI potential. In fact, Buffett seems to be quite cautious of the technology. Instead, he's warned investors that AI will give rise to an enormous amount of fraud, making scamming the biggest 'growth industry of all time'. Sticking to his principles Despite his hesitant stance, Buffett isn't blind to the benefits of this emerging technology. In the right hands, AI can be a remarkable tool with countless applications in finance, cybersecurity, automation, and work productivity among others. However, with so many businesses claiming to be the next big thing, Buffett and his team are remaining disciplined. They're focusing on the industries they understand the most, zooming in on the businesses with the widest competitive moats. That means rather than chasing speculative AI stocks, he's looking at the established players across the sectors that can leverage AI to improve their existing operations, using the proceeds to run phenomenal capital-return programmes. And right now, Apple seems to fit that bill. Exploring Apple's potential While Buffett's investment vehicle Berkshire Hathaway has trimmed its position in Apple throughout last year, it remains one of its largest holdings, representing 24% of the portfolio. As one of the largest consumer technology companies in the world, Apple produces an enormous amount of free cash flow driven by a loyal customer ecosystem. Since 2013, the company's been busy consistently buying back its own shares, with around $775bn spent over the last 12 years. To put this into perspective, that's enough money to buy the entirety of Visa with another $100bn to spare. And with management approving yet another $100bn in buybacks during 2025, the rewards for shareholders look set to continue, especially if the firm can deliver on its AI ambitions. So far, Apple has lagged when it comes to AI implementation. The rollout of Apple Intelligence has actually been quite slow and riddled with delays, which have seemingly continued into 2025. And the ongoing trade disruptions from newly-announced US tariffs aren't exactly helping matters, which have led to around a quarter of Apple's market-cap being lost in 2025. However, that might soon change. The company has a record number of revamped product launches in the second half of 2025. That includes four new iPhone models, and updates for its AirPods, Apple Watches, iPads, and MacBooks. And with plans to hire another 20,000 people over the next four years to expand its R&D capabilities, the firm might soon be catching up on the AI front, generating even more cash flow over the long run. Perhaps that's why Buffett continues to hold a significant chunk of shares. And it's why I think investors may want to take a closer look at this business. The post Here's what Warren Buffett says will be the ultimate growth industry! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool Zaven Boyrazian has no position in any of the shares mentioned. The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025
Yahoo
24 minutes ago
- Yahoo
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector
Gilead Sciences, Inc. (NASDAQ:GILD) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A physician and a patient having a discussion in a hospital about biopharmaceutical medicines. The company rose to prominence during the COVID-19 pandemic thanks to its antiviral drug remdesivir, one of the earliest approved treatments for the virus. However, despite its scientific breakthroughs and commercial achievements, Gilead has lagged behind the broader market over the past ten years, as investors remain cautious about its growth prospects and ability to deliver on its pipeline. That said, Gilead Sciences, Inc. (NASDAQ:GILD)'s cash position remained stable, which makes it one of the best dividend stocks in the pharma sector. In the first quarter of 2025, the company generated $1.8 billion in operating cash flow and had $7.9 billion available in cash and cash equivalents. During the quarter, it also returned $1 billion to investors through dividends. Gilead Sciences, Inc. (NASDAQ:GILD) currently offers a quarterly dividend of $0.79 per share and has a dividend yield of 2.90%, as of July 17. The company has raised its payouts every year since 2015. While we acknowledge the potential of GILD as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Why Amgen (AMGN) Could Be a Hidden Gem Among Dividend Pharma Stocks in 2025
Amgen Inc. (NASDAQ:AMGN) is included among the 14 Best Pharma Dividend Stocks to Buy in 2025. A pharmacist filling a prescription for a complex drug developed by the company. In 2023, the company finalized its $28 billion acquisition of Horizon Therapeutics, a smaller biotech firm. This move helped broaden Amgen's product portfolio and reduced its reliance on older drugs like Enbrel, which are expected to weigh on future revenue and profit growth. The acquisition also brought in new growth opportunities, especially with Tepezza, the first FDA-approved treatment for thyroid eye disease. In the first quarter of 2025, Amgen Inc. (NASDAQ:AMGN) reported revenue of $8.15 billion, which showed a 9.4% growth from the same period last year. The company reported strong global demand for its products in the first quarter. Management expressed confidence in its long-term growth outlook, citing continued success with new product launches and positive Phase 3 trial results for several treatments. Amgen Inc. (NASDAQ:AMGN)'s free cash flow for the quarter came in at $1.0 billion, up from $0.5 billion in the prior year period. Its operating cash flow was $1.4 billion, compared to $0.7 billion in the same period last year. The company also returned $1.3 billion to shareholders through dividends during the quarter. Currently, it offers a quarterly dividend of $2.38 per share and has a dividend yield of 3.19%, as of July 17. The company has raised its payouts since the inception of its dividend policy in 2011. While we acknowledge the potential of AMGN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and . Disclosure: None. Sign in to access your portfolio
